English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/73502
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds

AuthorsRedondo, Miriam ; Brea, José; Pérez, Daniel I.; Soteras, Ignacio ; Val, Cristina; Pérez, Concepción; Morales-García, José A. ; Alonso-Gil, Sandra ; Paul-Fernández, Nuria ; Martín-Álvarez, Rocío ; Cadavid, María Isabel; Loza, María Isabel; Pérez Castillo, Ana ; Mengod Los Arcos, Guadalupe ; Campillo, Nuria E. ; Martínez, Ana ; Gil, Carmen
Issue Date2012
PublisherAmerican Chemical Society
CitationJournal of Medicinal Chemistry 55(7): 3274-3284 (2012)
AbstractPhosphodiesterase (PDE) 7 is involved in proinflammatory processes, being widely expressed both on lymphocytes and on certain brain regions. Specific inhibitors of PDE7 have been recently reported as potential new drugs for the treatment of neurological disorders because of their ability to increase intracellular levels of cAMP and thus to modulate the inflammatory process, as a neuroprotective well-established strategy. Multiple sclerosis is an unmet disease in which pathologies on the immune system, T-cells, and specific neural cells are involved simultaneously. Therefore, PDE7 inhibitors able to interfere with all these targets may represent an innovative therapy for this pathology. Here, we report a new chemically diverse family of heterocyclic PDE7 inhibitors, discovered and optimized by using molecular modeling studies, able to increase cAMP levels in cells, decrease inflammatory activation on primary neural cultures, and also attenuate the clinical symptoms in the experimental autoimmune encephalomyelitis (EAE) mouse model. These results led us to propose the use of PDE7 inhibitors as innovative therapeutic agents for the treatment of multiple sclerosis. © 2012 American Chemical Society.
Publisher version (URL)http://dx.doi.org/10.1021/jm201720d
URIhttp://hdl.handle.net/10261/73502
DOI10.1021/jm201720d
Identifiersdoi: 10.1021/jm201720d
issn: 0022-2623
e-issn: 1520-4804
Appears in Collections:(IQM) Artículos
(IIBM) Artículos
(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
Effect of phosphodiesterase.pdf713,55 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.